<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01268124</url>
  </required_header>
  <id_info>
    <org_study_id>3253A1-1001-JA</org_study_id>
    <nct_id>NCT01268124</nct_id>
  </id_info>
  <brief_title>Study Evaluating The Safety and Tolerability of HTC-867 in Healthy Japanese Subjects</brief_title>
  <official_title>Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HTC-867 Administered Orally to Healthy Japanese Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wyeth is now a wholly owned subsidiary of Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1, randomized (a process that is used to decide whether you will take study&#xD;
      drug or a placebo during the study), inpatient study which will assess the safety and&#xD;
      tolerability of HTC-867 in healthy male Japanese subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety will be measured by vitals signs, labs and electrocardiograms (ECG's).</measure>
    <time_frame>7 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics.</measure>
    <time_frame>7 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HTC-867</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:&#xD;
&#xD;
          1. Men aged 20 to 45 years inclusive at screening. Sexually active men must agree to use&#xD;
             a medically acceptable form of contraception during the study and continue it for 12&#xD;
             weeks after test article administration.&#xD;
&#xD;
          2. Body mass index (BMI) in the range of 17.6 to 26.4 kg/m2 and body weight ≥45 kg.&#xD;
&#xD;
             BMI is calculated by taking the subject's weight, in kilograms, divided by the square&#xD;
             of the subject's height, in meters, at screening: BMI = Weight (kg)/[Height (m)]2.&#xD;
&#xD;
          3. Healthy as determined by the investigator on the basis of screening evaluations.&#xD;
&#xD;
          4. Nonsmoker or smoker of fewer than 10 cigarettes per day as determined by history. Must&#xD;
             be able to abstain from smoking during the inpatient stay.&#xD;
&#xD;
          5. Have a high probability for compliance with and completion of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Medical History&#xD;
&#xD;
          1. Presence or history of any disorder that may prevent the successful completion of the&#xD;
             study.&#xD;
&#xD;
          2. Any unstable medical condition.&#xD;
&#xD;
          3. History of seizures.&#xD;
&#xD;
          4. History of cardiac disorders (other than hypertension) including but not limited to&#xD;
             valvular disease, congestive heart failure, angina pectoris, myocardial infarction, or&#xD;
             arrhythmia.&#xD;
&#xD;
          5. Any significant cardiovascular disease, hepatic, renal, respiratory, gastrointestinal,&#xD;
             endocrine, immunologic, dermatologic, hematologic, neurologic, or psychiatric disease.&#xD;
&#xD;
          6. Any surgical or medical condition that may interfere with the absorption,&#xD;
             distribution, metabolism, or excretion of the test article (eg, resection of liver,&#xD;
             kidney, gallbladder, or gastrointestinal tract).&#xD;
&#xD;
          7. Acute disease state (eg, nausea, vomiting, infection, fever, or diarrhea) within 7&#xD;
             days before study day 1).&#xD;
&#xD;
          8. History of drug abuse within 1 year before study day 1.&#xD;
&#xD;
          9. Admitted alcohol abuse or history of alcohol use that may interfere with the subject's&#xD;
             ability to comply with the protocol requirements.&#xD;
&#xD;
             Physical and Laboratory Findings&#xD;
&#xD;
         10. Clinically significant electrocardiogram (ECG) abnormalities.&#xD;
&#xD;
         11. Any clinically important deviation from normal limits in physical examination&#xD;
             findings, vital sign measurements, 12-lead ECGs, or clinical laboratory test results.&#xD;
&#xD;
         12. Positive serologic findings for human immunodeficiency virus (HIV) antigen and&#xD;
             antibodies, hepatitis B surface antigen (HBsAg), and hepatitis C virus (HCV)&#xD;
             antibodies.&#xD;
&#xD;
         13. Positive findings of urine drug screen (eg, amphetamines, barbiturates,&#xD;
             benzodiazepines, cannabinoids, cocaine, opiates, and phencyclidine [PCP]).&#xD;
&#xD;
         14. Troponin T or CK-MB levels above reference range at screening. Allergies and Adverse&#xD;
             Drug Reactions&#xD;
&#xD;
         15. History of any clinically important drug allergy (eg, relapsing dermatitis, drug&#xD;
             hypersensitivity, drug allergy, hypersensitivity to ingredient in the test articles,&#xD;
             angioedema).&#xD;
&#xD;
             Prohibited Treatments&#xD;
&#xD;
         16. Use of any investigational drug within 90 days before study day 1 or prescription drug&#xD;
             within 30 days before study day 1.&#xD;
&#xD;
         17. Tobacco use or the consumption of any caffeine-containing products (eg, coffee, tea,&#xD;
             chocolate, or carbonated beverages) or alcoholic beverages within 72 hours before&#xD;
             study day 1 until the end of the inpatient confinement period.&#xD;
&#xD;
         18. Consumption of grapefruit or grapefruit-containing products within 72 hours before&#xD;
             study day 1 until the end of the inpatient confinement period.&#xD;
&#xD;
         19. Use of any over-the-counter drugs, including herbal supplements (except for the&#xD;
             occasional use of vitamins ≤100% of the recommended daily allowance), within 14 days&#xD;
             before study day 1 (St. John wort is prohibited within 30 days of study day 1).&#xD;
&#xD;
         20. Donation of blood within 90 days before study day 1. Others&#xD;
&#xD;
         21. Subjects deemed by the investigator to be inappropriate according to the inclusion&#xD;
             criteria in the study and according to the screening examination.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Wyeth is now a wholly owned subsidiary of Pfizer</affiliation>
  </overall_official>
  <verification_date>February 2010</verification_date>
  <study_first_submitted>January 28, 2010</study_first_submitted>
  <study_first_submitted_qc>December 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2010</study_first_posted>
  <last_update_submitted>December 28, 2010</last_update_submitted>
  <last_update_submitted_qc>December 28, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 29, 2010</last_update_posted>
  <responsible_party>
    <name_title>Wyeth (Registry Contact: Clinical Trial Registry Specialist)</name_title>
    <organization>Wyeth</organization>
  </responsible_party>
  <keyword>Japanese</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

